Defining The Role Of The Major Subsets Of Renal Mononuclear Phogocytes
Funder
National Health and Medical Research Council
Funding Amount
$614,227.00
Summary
Chronic Kidney Disease (CKD) is a major cause of death and morbidity in Australia, and currently therapeutic options are limited. Renal mononuclear phagocytes (rMP) are important immune cells which play a central role in health and disease of the kidney. However, rMP are a heterogenous group of cells with a poorly defined role in the development and progression of CKD. We will define the role of major subsets of rMP in CKD, and explore their potential for treating CKD.
Therapeutic Potential Of Peritoneal Mononuclear Phagocytes From Peritoneal Dialysis Patients
Funder
National Health and Medical Research Council
Funding Amount
$375,817.00
Summary
Mononuclear phagocytes (MP) are key cells which are now being used to treat various diseases. In Australia, more than 10 million end stage kidney disease(ESKD) patients are treated with chronic dialysis, and more than 20% of them are on peritoneal dialysis (PD). Each PD patient discards more than 20 million MP in dialysate daily. We will explore the possibility of using these MP to treat diseases including transplant rejection.
Optimising The Therapeutic Efficacy Of Anti-inflammatory Macrophages For Use In Chronic Kidney Diseases
Funder
National Health and Medical Research Council
Funding Amount
$605,096.00
Summary
Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia. Current treatments that are able to delay progression for CKD are limited. As a consequence, more than 2300 additional Australians need kidney replacement each year and many more die of kidney failure. We have reduced and prevented injury in a mouse model of CKD by administering protective white blood cells - macrophages. This project will modify macrophages ex vivo to optimize them for use as a therapy for CKD.